RA
CELG

Royce & Associates’s Celgene Corp CELG Stock Holding History

Royce & Associates’s Portfolio CELG Stock Details CELG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-1,200
Closed -$84K – 1508
2014
Q1 		$84K Sell
1,200
-600
-33% -$47.5K ﹤0.01% 1353
2013
Q4 		$152K Buy
+1,800
New +$142K ﹤0.01% 1328
2013
Q3 		– Sell
-3,600
Closed -$211K – 1524
2013
Q2 		$211K Buy
+3,600
New +$217K ﹤0.01% 1288

Other funds holding CELG

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Royce & Associates's CELG Position: Q2 2014 in Review

Royce & Associates sold out of Celgene Corp (CELG) in Q2 2014, closing a stake of 1,200 shares — an estimated $84K sold.

Royce & Associates first reported a position in CELG in Q2 2013 and held it in 3 quarters. The position peaked at $211K in Q2 2013. 995 funds tracked by Wall St. Rank hold CELG as of Q2 2014.

  • Royce & Associates reported no remaining Celgene Corp position as of Q2 2014 after selling out during the quarter.
  • Royce & Associates sold 1,200 Celgene Corp shares in Q2 2014, an estimated $84K.
  • Royce & Associates first reported a position in Celgene Corp in Q2 2013 and held it in 3 quarters.
  • Royce & Associates's Celgene Corp position peaked at $211K in Q2 2013.
  • 995 funds tracked by Wall St. Rank held Celgene Corp as of Q2 2014.

Based on Royce & Associates's 13F filing for Q2 2014, filed 11 Aug 2014.